Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

NCT06982859 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06982859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06982859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 2, 2025
Completion date
January 31, 2027
Enrollment
95 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, insulin sensitivity